Question 1

What is Nipah virus?

Accepted Answer

Nipah virus (NiV) is a highly lethal bat-borne paramyxovirus — first identified in 1999 when it killed 105 pig farmers and abattoir workers in Malaysia and Singapore (105 deaths from 283 cases). It is maintained in Pteropus fruit bats across South and Southeast Asia. NiV causes severe encephalitis with case fatality rates of 40-75% — among the highest of any human pathogen — with documented human-to-human transmission in Bangladesh and potential for pandemic spread.

Question 2

Where does Nipah come from?

Accepted Answer

Nipah virus is maintained in Pteropus fruit bats (flying foxes) — large fruit-eating bats found across South and Southeast Asia, Australia and the Pacific. Bats are lifelong carriers but do not develop disease. Virus is shed in bat saliva (on fruit they feed on), urine and reproductive secretions. The geographic range of Pteropus bats vastly exceeds the current distribution of known human NiV cases — suggesting that spillover events are underdetected or that other factors (viral strains, intermediate hosts, exposure levels) determine where outbreaks occur.

Question 3

How is Nipah transmitted to humans?

Accepted Answer

Bangladesh (dominant route globally): drinking raw date palm sap (a traditional winter drink) contaminated with bat urine or saliva while bats feed on the collectors overnight. Malaysia 1999 outbreak: infected pigs (intermediate host) transmitted to pig farmers and abattoir workers. Kerala, India outbreaks: unclear initial route (possibly fruit contaminated by bats); subsequent human-to-human transmission in families and hospital. Human-to-human: respiratory droplets and direct contact with infected secretions — documented particularly in family caregivers and healthcare workers.

Question 4

Why is Nipah considered a pandemic threat?

Accepted Answer

Nipah has characteristics that make it deeply concerning: extremely high case fatality rate (40-75%); documented human-to-human transmission (unlike most bat viruses); wide geographic range of reservoir bats across South and Southeast Asia; no approved vaccine or treatment; and a different strain with higher pandemic potential may theoretically emerge. Modelling of a hypothetical Nipah pandemic with respiratory adaptation shows mortality estimates comparable to or exceeding the 1918 influenza pandemic. WHO R&D Blueprint and CEPI treat NiV as one of the highest-priority pathogens for emergency vaccine development.

Question 5

Is there treatment for Nipah?

Accepted Answer

No approved antiviral or vaccine exists. Supportive care in ICU is the primary treatment: mechanical ventilation for respiratory failure; seizure management; electrolyte management. Ribavirin (an antiviral) was used in Malaysia without definitive efficacy data. Monoclonal antibody m102.4 (targeting NiV G glycoprotein) showed promising animal model efficacy and was used on a compassionate basis in several human cases — Phase 1 safety data are available. The neutralising monoclonal antibody has moved toward clinical evaluation through CEPI partnerships.

Question 6

What vaccines are in development?

Accepted Answer

CEPI has invested significantly in NiV vaccine development as a top-priority pathogen: Moderna's mRNA-1215 (encoding NiV G glycoprotein) entered Phase 1 human safety trials in 2022 — the first human NiV vaccine trial. Additional candidates in development include recombinant vesicular stomatitis virus (rVSV) vectors, virosomes and protein subunit vaccines. All current vaccine candidates target the NiV G (attachment) or F (fusion) glycoproteins. The 100 Days Mission — developing vaccines within 100 days of a declared outbreak — includes NiV as a specific target.

Question 7

What happened in the 2023 Kerala outbreak?

Accepted Answer

Kerala, India experienced a NiV outbreak in September 2023 (Kozhikode district) — 6 cases, 2 deaths. Kerala's rapid response — using genome sequencing for diagnosis, contact tracing (700+ contacts), and implementation of strict infection prevention measures — successfully contained the outbreak. The 2023 outbreak used Bangladesh-lineage NiV (NiV-B), suggesting different epidemiology from the 2018 Kerala outbreak (2 deaths). NiV-B has been associated with human-to-human transmission, increasing concern.

Question 8

What is the date palm sap risk?

Accepted Answer

In Bangladesh, drinking raw date palm sap (khejur rash) — tapped from date palms overnight — is the primary NiV transmission route. Pteropus bats feed on the sap dripping from collectors attached to trees at night, contaminating it with urine and saliva. Covering sap collectors with bamboo skirts to exclude bats has been shown in community studies to nearly eliminate NiV contamination. Public health campaigns in Bangladesh encourage covering collectors and avoiding raw sap.

Question 9

How should healthcare workers protect themselves?

Accepted Answer

Nipah patients require strict contact and droplet precautions — full PPE including: gown, gloves, N95 mask (or higher), eye protection, and hand hygiene. Healthcare workers without PPE are at high risk — multiple healthcare worker deaths have occurred in Bangladesh and Kerala outbreaks. In the 2023 Kerala outbreak, Kerala's well-practised infection prevention programme (from COVID-19 experience) prevented further healthcare worker transmission. Patients suspected of NiV should be isolated and PPE donned before any contact.

Question 10

How does GMJ News cover Nipah virus?

Accepted Answer

GMJ News covers WHO Nipah R&D Blueprint designation, outbreak situation reports (particularly Kerala and Bangladesh), mRNA vaccine development, monoclonal antibody evidence and pandemic preparedness implications. Nipah is a key emerging infectious disease for PHIG's health security surveillance and the Georgian Medical Journal's global health coverage.

GMJ News

Nipah Virus

Key messages

Key statistics

Glossary of key terms

Latest GMJ coverage

Frequently asked questions 12 Q&A — structured for Google featured snippets and AI discovery

Knowledge hub: guidelines, conventions and reports

Organizations working in migration and health

Related health topics

Company